说明:双击或选中下面任意单词,将显示该词的音标、读音、翻译等;选中中文或多个词,将显示翻译。
您的位置:首页 -> 词典 -> 纤溶酶原激活物抑制剂-1
1)  plasminogen activator inhibitor-1
纤溶酶原激活物抑制剂-1
1.
Expression of plasminogen activator inhibitor-1 in the placentas of pre-elampsia;
子痫前期患者胎盘组织中纤溶酶原激活物抑制剂-1的表达
2.
Objective To analyze mRNA and protein expressions of plasminogen activator and plasminogen activator inhibitor-1 using microdissection and quantitative real-time PCR,and to analyse their associations with microvascular diseases in IgA nephropathy.
目的应用激光微切割和定量PCR技术检测IgA肾病纤溶酶原激活物(PA)和纤溶酶原激活物抑制剂-1(PAI-1)的表达及其在IgA肾病毛细血管病变中的作用。
2)  PAI-1
纤溶酶原激活物抑制剂-1
1.
Advanced glycation end products induce expression of PAI-1 in cultured human proximal tubular epithelial cells through NADPH oxidase dependent pathway
晚期糖基化终产物诱导人近端肾小管上皮细胞纤溶酶原激活物抑制剂-1表达上调并活化NADPH氧化酶
2.
OBJECTIVE To investigate the effect of ginsenoside Rb1 on production of NO and expression of transforming growth factor beta-1(TGF-β1)、plasminogen activator inhibitor-1(PAI-1)and tissue factor(TF)in human endothelial cells,and explore the protective mechanism of ginsenoside Rb1 on endothelial cells and determine appropriate Rb1 intervention dosage.
方法:体外培养人脐静脉内皮细胞,采用不同浓度的人参皂苷Rb1和BU干预,以硝酸还原酶法检测HUVEC培养上清液中一氧化氮水平,ELISA方法检测TGF-β1、纤溶酶原激活物抑制剂-1(PAI-1)和TF的蛋白含量,实时荧光定量PCR检测HUVECTGF-β1、PAI-1和TFmRNA的表达。
3.
Histology and immunofluorescence assay were used to detect plasminogen activator inhibitor-1(PAI-1) by a laser scanning confocal microscope in mammary gland slices.
对昆明种白小鼠乳腺发育进行了组织学观察,并利用激光扫描共聚焦显微系统对脂肪细胞相关因子纤溶酶原激活物抑制剂-1(PAI-1)的表达进行了免疫荧光检测。
3)  Plasminogen activator inhibitor type-1
纤溶酶原激活物抑制剂-1
1.
Effect of linoleic acid on the expression of plasminogen activator inhibitor type-1 and its mechanism;
亚油酸对纤溶酶原激活物抑制剂-1表达的影响及其机制
2.
Objective: To explore the effect of specific cyclooxygenase-2 inhibitor(Rofecoxib) on the expression of plasminogen activator inhibitor type-1 in MRL/lpr mice.
目的:探讨特异性环氧化酶(COX)-2抑制剂(Rofecoxib)对M RL/lpr自发狼疮小鼠肾脏纤溶酶原激活物抑制剂-1(PAI-1)表达的影响。
3.
Objective: To investigate the primary culture method of endothelial cells from human umbilical vein ,study the effect of different concentration of lipopolysacch-aride(LPS) and glucose (GLU) on the expression of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1),and help to study the mechanism of thrombus disease .
目的:探讨人脐静脉内皮细胞(Human umbilical endothelial cell,HUVEC)的分离培养及鉴定方法,在建立体外血管内皮细胞原代培养模型的基础上观察不同浓度细菌内毒素(Lipopolyssacarides,LPS)和葡萄糖(Glucose,GLU) 对血管内皮细胞组织型纤溶酶原激活物(Tissue plasminogen activator, t-PA)和纤溶酶原激活物抑制剂-1(Plasminogen activator inhibitor-1,PAI-1)表达的影响,为进一步研究各种血栓性疾病的形成机制提供实验依据。
4)  Plasminogen activator inhibitor 1
纤溶酶原激活物抑制剂-1
1.
Aberrant production of adipose-derived adipokines, especially adiponectin (AD), plasminogen activator inhibitor 1 (PAI-1) and interleukin-6 (IL-6), is now believed.
肥胖时ADS的异常调节,尤其是脂联素(adiponectin,AD)、纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor 1,PAI-1)及白介素6(interleukin-6,IL-6)的异常,是导致肥胖相关的胰岛素抵抗及CVD发生的重要原因。
5)  plasminogen activator inhibitor 1
纤溶酶原激活抑制物1
6)  atherrosclerosis
纤溶酶原激活抑制物-1
1.
Objective Raising atherrosclerosis model, to observe the the local expression of angiotensin II (Ang II ), transforming growth factor-β1 (TGF-β1)、plasminogen activator inhibitor-1 (PAI-1) and type IV collagen in renal tissue and to approach the renal protective effect of Captopril and Valsartan through blocking renin-angiotonin system(RAS) on various level.
目的建立动脉粥样硬化(atherosclerosis,AS)模型,观察在AS形成时肾脏组织中血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)、转化生长因子-β1(transforming growth factor-β1,TGF-β1)、纤溶酶原激活抑制物-1(plasminogen activator inhibitor-1,PAI-1)和Ⅳ型胶原蛋白的表达以及卡托普利与缬沙坦从不同水平阻断肾素-血管紧张素系统(renin-angiotonin system,RAS)后对肾脏的保护作用。
补充资料:纤溶酶原激活剂
分子式:
CAS号:

性质:是一组蛋白酶,使纤溶酶激活生成有活性的纤溶酶。它们主要包括:(1)组织纤溶酶激动剂(tPA),一种丝氨酸蛋白酶,创伤或应激时从血管内皮释放入血,只有同纤维蛋白结合时才有激活纤溶酶原的活性;(2)尿激酶,对纤维蛋白选择性较低,是某些内皮细胞系合成、经外分泌管道(如肾小管)分泌,可能参与清除沉积在管道内的纤维蛋白;(3)链激酶,临床上用于裂解纤维蛋白,其选择性较差,可作用于液相中的纤溶酶原,也可作用于纤维蛋白血块中的纤溶酶原,链激酶不是蛋白酶,但与纤溶酶原结合成复合物后构象改变,显示蛋白水解酶活性。

说明:补充资料仅用于学习参考,请勿用于其它任何用途。
参考词条